	US 12,214,038 B2
	Compositions and methods for cancer immunotherapy
Andrea Facciabene, Philadelphia, PA (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Appl. No. 15/328,047
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
PCT Filed Jul. 22, 2015, PCT No. PCT/US2015/041450 § 371(c)(1), (2) Date Jun. 23, 2017, PCT Pub. No. WO2016/014613, PCT Pub. Date Jan. 28, 2016.
Claims priority of provisional application 62/027,691, filed on Jul. 22, 2014.
Prior Publication US 2017/0216419 A1, Aug. 3, 2017
Int. Cl. A61K 39/00 (2006.01); A61K 35/15 (2015.01); A61K 35/12 (2015.01)

CPC A61K 39/4622 (2023.05) [A61K 35/15 (2013.01); A61K 39/4615 (2023.05); A61K 39/464499 (2023.05); A61K 2035/122 (2013.01)]

14 Claims

1. A tumor-specific immunogenic composition comprising: an antigen-presenting cell pulsed with a tumor mitochondrial protein lysate from a renal cancer or a liver cancer, and wherein said antigen-presenting cell is a dendritic cell.